Filtered By:
Management: Medicare
Procedure: Heart Valve Surgery

This page shows you your search results in order of date.

Order by Relevance | Date

Total 26 results found since Jan 2013.

Benchmarking Outcomes of Surgical Aortic Valve Replacement in Patients with Bicuspid Aortic Valves
CONCLUSIONS: In this nationally-representative study, 30-day mortality was similar but risk-adjusted 5-year mortality was significantly lower in bicuspid patients undergoing isolated SAVR compared to tricuspid patients, specifically low-risk and normal left ventricular ejection fraction patients. This analyses provides a much-needed 5-year longitudinal national-level benchmark to better inform the discussion of transcatheter vs SAVR in bicuspid patients.PMID:37454786 | DOI:10.1016/j.athoracsur.2023.06.026
Source: The Annals of Thoracic Surgery - July 16, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Sameer A Hirji Zachary Wegermann Sreekanth Vemulapalli Paige Newell Maria Grau-Sepulveda Sean O'Brien Vinod H Thourani Vinay Badhwar Tsuyoshi Kaneko Source Type: research

Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial
CONCLUSIONS: For patients with severe aortic stenosis and low surgical risk similar to those enrolled in the PARTNER 3 trial, transfemoral TAVR with the SAPIEN 3 valve is cost saving compared with SAVR at 2 years and is projected to be economically attractive in the long run as long as there are no substantial differences in late death between the 2 strategies. Long-term follow-up will be critical to ultimately determine the preferred treatment strategy for low-risk patients from both a clinical and economic perspective.PMID:37154049 | DOI:10.1161/CIRCULATIONAHA.122.062481
Source: Circulation - May 8, 2023 Category: Cardiology Authors: Benjamin Z Galper Khaja M Chinnakondepalli Kaijun Wang Elizabeth A Magnuson Michael Lu Vinod H Thourani Susheel Kodali Raj Makkar Howard C Herrmann Samir Kapadia Mathew Williams John Webb Craig R Smith Michael J Mack Martin B Leon David J Cohen PARTNER In Source Type: research

Reply: Stentless versus stented bioprosthetic root replacement in the medicare population and the wisdom of crowds
In our recent analysis of long-term outcomes of aortic root operations in the United States among Medicare beneficiaries using the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS-ACSD) and Centers for Medicare and Medicaid Services linked data for patients aged 65 years or older undergoing elective aortic root surgery, we concluded that the bioprosthetic Bentall operation should be the procedure of choice in this population due to improved survival and lower stroke risk compared with the use of the mechanical Bentall, and lower risk of aortic valve reintervention compared with valve-sparing aortic root replacement.
Source: The Journal of Thoracic and Cardiovascular Surgery - April 21, 2023 Category: Cardiovascular & Thoracic Surgery Authors: G. Chad Hughes Tags: Letter to the Editor Source Type: research

Reply from the authors: Stentless versus stented bioprosthetic root replacement in the medicare population and the wisdom of crowds
In our recent analysis of long-term outcomes of aortic root operations in the United States among Medicare beneficiaries using the Society of Thoracic Surgeons Adult Cardiac Surgery Database (STS-ACSD) and Centers for Medicare and Medicaid Services linked data for patients aged 65 years or older undergoing elective aortic root surgery, we concluded that the bioprosthetic Bentall operation should be the procedure of choice in this population due to improved survival and lower stroke risk compared with the use of the mechanical Bentall, and lower risk of aortic valve reintervention compared with valve-sparing aortic root replacement.
Source: The Journal of Thoracic and Cardiovascular Surgery - April 21, 2023 Category: Cardiovascular & Thoracic Surgery Authors: G. Chad Hughes Tags: Adult: Aorta: Letters to the Editor Source Type: research

Transcatheter vs Surgical Aortic Valve Replacement in Pure Native Aortic Regurgitation
CONCLUSIONS: In Medicare patients with pure native AR, TAVR with the current commercially available transcatheter valves has comparable short-term outcomes. Although long-term outcomes were inferior to SAVR, the possibility of residual confounding, biasing long-term outcomes, given older and frailer TAVR patients, cannot be excluded.PMID:36967709 | DOI:10.1016/j.athoracsur.2022.09.016
Source: The Annals of Thoracic Surgery - March 27, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Amgad Mentias Marwan Saad Venu Menon Grant W Reed Zoran Popovic Douglas Johnston Leonardo Rodriguez Marc Gillinov Brian Griffin Hani Jneid Sidakpal Panaich Samir Kapadia Lars G Svensson Milind Y Desai Source Type: research

Aortic Annular Enlargement in the Elderly: Short and Long-Term Outcomes in the United States.
CONCLUSIONS: These data suggest annular enlargement during SAVR is associated with increased short-term risk in a Medicare population. Survival curves crossed after three years, which may portend a benefit in select patients. However, annular enlargement is still only done in the minority of patients who are at risk for PPM. PMID: 33421392 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - January 6, 2021 Category: Cardiovascular & Thoracic Surgery Authors: Mehaffey JH, Hawkins RB, Wegermann ZK, Grau-Sepulveda MV, Fallon JM, Brennan JM, Thourani VH, Badhwar V, Ailawadi G Tags: Ann Thorac Surg Source Type: research

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings from the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study.
Conclusions: In the CoreValve HiR and SURTAVI trials, ascertainment of trial primary endpoints using claims reproduced both the magnitude and direction of treatment effect compared with adjudicated event data, but non-fatal and non-procedural secondary outcomes were not as well reproduced. Use of claims to substitute for adjudicated outcomes in traditional trial treatment comparisons may be valid and feasible for all-cause mortality and certain procedural outcomes, but may be less suitable for other endpoints. PMID: 32436390 [PubMed - as supplied by publisher]
Source: Circulation - May 20, 2020 Category: Cardiology Authors: Strom JB, Faridi KF, Butala NM, Zhao Y, Tamez H, Valsdottir LR, Brennan JM, Shen C, Popma JJ, Kazi DS, Yeh RW Tags: Circulation Source Type: research

Outcomes of Transcatheter Aortic Valve Replacement in Patients with Bicuspid Aortic Valve Disease: A Report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.
Conclusions: Using current generation devices, procedural, post-procedural, and 1-year outcomes were comparable following TAVR for bicuspid AV vs. tricuspid AV disease. With newer generation devices, TAVR is a viable treatment option for bicuspid AV patients. PMID: 32098500 [PubMed - as supplied by publisher]
Source: Circulation - February 25, 2020 Category: Cardiology Authors: Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, Tuzcu EM, Thourani VH, Harrison JK, Brennan JM Tags: Circulation Source Type: research

Use of left atrial appendage occlusion among older cardiac surgery patients with preoperative atrial fibrillation: a national cohort study
ConclusionsSubstantial variability in use of S-LAAO exists. In many instances, the procedure is being deferred in the patients that may be poised to benefit the most (i.e., those with increased CHA2DS2-VASc score-defined stroke risk).
Source: Journal of Interventional Cardiac Electrophysiology - February 2, 2019 Category: Cardiology Source Type: research

Boston Scientific closes $270m Claret Medical buy
Boston Scientific (NYSE:BSX) said yesterday that it closed the $270 million buyout of Claret Medical and its Sentinel device, including a $50 million earnout pegged to a reimbursement win that just came in. Claret’s Sentinel device is designed to trap and remove debris dislodged during transcatheter aortic valve replacements to prevent stroke and other neurological damage. The deal, announced July 20, originally called for an up-front cash payment of $220 million plus the $50 million reimbursement milestone. That milestone was reached when the Centers for Medicare & Medicaid Services granted a New Technology Add...
Source: Mass Device - August 3, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Mergers & Acquisitions Replacement Heart Valves Wall Street Beat Boston Scientific Claret Medical Inc. Source Type: news